Recruiting Pulmonary Embolism Studies in Tucson
A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
This study is open to adults with type 2 diabetes, high blood pressure, and cardiovascular disease. People can join the study if they have these conditions and do not have a history of heart failure. ...
VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)
This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic ef...
ABTECT - Maintenance
This is a multicenter, randomized, placebo-controlled study to evaluate the long-term efficacy and safety of ABX464 50mg and 25mg administered once daily (QD) as maintenance therapy in subjects with m...
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from pati...
Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
The purpose of this study is to assess the safety and efficacy (including durability) of up to 2 REACT injections given 3 months (+30 days) apart and delivered percutaneously into biopsied and non-bio...
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
The main purpose of this study is to see how orforglipron, compared with placebo, helps improve glycemic control in participants with obesity or with overweight and type 2 diabetes. This trial is part...
Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)
The primary objective of this study is to assess the 6-month safety of DBV712 250 micrograms (mcg) in subjects 1 through 3 years of age with peanut allergy....
Improving Mobility After Revascularization in Peripheral Artery Disease
Lower extremity revascularization combined with supervised exercise significantly improves walking performance compared to revascularization alone in people who have PAD without limb threatening ische...
A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients
The purpose of this study is to evaluate the efficacy, safety and tolerability of QCZ484 or placebo, given subcutaneously, every 6 months, at different dose levels in patients with mild to moderate hy...
Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy
The study will enroll 200 women newly diagnosed with peripartum cardiomyopathy within 5 months postpartum in a randomized placebo controlled trial of bromocriptine therapy to evaluate its impact on my...
LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF
This study will evaluate the efficacy of TNX-103 (oral levosimendan) compared with placebo in subjects with PH-HFpEF as measured by the change in 6-Minute Walk Distance (6 MWD; Day 1 to Week 12)....
A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)
Researchers are looking for ways to treat a type of liver disease caused by elevated liver fat, called metabolic dysfunction-associated steatohepatitis (MASH). MASH was formerly called non-alcoholic s...
CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)
This study is a Phase 1b/2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-103. The approximately 208-da...
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
The main purpose of this study is to evaluate additional dosing options for dulaglutide in pediatric participants with Type 2 Diabetes. Participation in this study will last about 8 months....
An Open-Label Pilot Study of VTX2735 in Recurrent Pericarditis
This is a study to understand if taking VTX2735 is safe and effective in participants diagnosed with Recurrent Pericarditis (RP). Approximately 30 patients will take VTX2735. The study consists of a ...
About Pulmonary Embolism Clinical Trials in Tucson
Pulmonary embolism (PE) is a blockage of an artery in the lungs, usually caused by blood clots that travel from the deep veins of the legs. It can be life-threatening and requires immediate medical attention. Treatment includes anticoagulants and in severe cases, thrombolytic therapy.
There are currently 15 pulmonary embolism clinical trials recruiting participants in Tucson, ARIZONA. These studies are seeking a combined 18,158 participants. Research is being sponsored by Boehringer Ingelheim, Viking Therapeutics, Inc., Abivax S.A. and 11 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Pulmonary Embolism Clinical Trials in Tucson — FAQ
Are there pulmonary embolism clinical trials in Tucson?
Yes, there are 15 pulmonary embolism clinical trials currently recruiting in Tucson, ARIZONA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Tucson?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Tucson research site will contact you about next steps.
Are clinical trials in Tucson free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Tucson studies also compensate for your time and travel.
What pulmonary embolism treatments are being tested?
The 15 active trials in Tucson are testing new therapies including novel drugs, biologics, and treatment approaches for pulmonary embolism.
Data updated March 2, 2026 from ClinicalTrials.gov